reactive thrombocytosis


Also found in: Dictionary, Thesaurus, Encyclopedia.

reactive thrombocytosis

Reactive hyperthrombocytosis platelet count of ≥ 800 x 109/L–US = ≥ 800 000/µl, seen in ± 1:200 of hospital Pts Associations Acute and chronic inflammation–eg, RA, SLE, malignancies, neonatal RDS, and after hemorrhage, surgery, trauma; in some cases of RHT–eg, burns, hypothermia, preeclampsia, low platelet numbers are present. Cf Essential thrombocytosis, Respiratory distress syndrome.

thrombocytosis

increase in the number of platelets in the circulating blood. See also thrombocythemia.

autonomous thrombocytosis
one resulting from a myeloproliferative disorder.
reactive thrombocytosis
one occurring in association with acute hemorrhage, trauma, neoplasia, etc.
References in periodicals archive ?
We hope that further studies performed on larger number of patients--reactive thrombocytosis- and controls, additionally including thrombo-cythemic disorders, with the possibility of encountering higher platelet counts and analyzing additional criteria that could influence viscosity can illuminate the dark spots of current clinical practice in reactive thrombocytosis which seems innocent at the present.
Reactive thrombocytosis and stroke following cardiopulmonary bypass surgery: Case report on three patients.
Reactive thrombocytosis is a common cause of thrombocytosis (2, 4).
Essential thrombocytosis is a diagnosis of exclusion by ruling out known causes of reactive thrombocytosis.
Reactive thrombocytosis is thought to result from overproduction of one or more thrombopoietic factors that act on megakaryocytes or their precursors (3).
Hsu HC, Tsai WH, Jiang ML, et al: Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis.
Cerutti A, Custodi P, Duranti M, et al: Thrombopoietin levels in patients with primary and reactive thrombocytosis.
Wang JC, Chen C, Novetsky AD, et al: Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.
Evidence of an increased in vitro thrombotic tendency in patients with reactive thrombocytosis is of paramount importance in proving the cause and effect relationship between reactive thrombocytosis and thromboembolism.
After obtaining Royal Perth Hospital Ethics Committee approval (EC2009/098), a total of 48 patients with reactive thrombocytosis, defined by platelet count >500 x [10.
9]/L; examination of a bone marrow specimen to demonstrate the characteristic abnormalities of the megakaryocytic lineage; and exclusion of reactive thrombocytosis, polycythemia vera, primary myelofibrosis, chronic myelogenous leukemia, myelodysplastic syndrome or other myeloid neoplasm.
Demonstration of JAK2 V617F or other clonal marker, or in the absence of JAK2 V617F, no evidence for reactive thrombocytosis.

Full browser ?